D. A. Reardon, A. Desjardins, K. B. Peters, S. Gururangan, J. H. Sampson, R. E. Mclendon, J. E. Herndon,A. Bulusu, S. Threatt, A. H. Friedman, J. J. Vredenburgh and H. S. Friedman, “Phase II Study of Carboplatin, Irinotecan, and Bevacizumab for Bevacizumab Naive, Recurrent Glioblastoma,” Journal of Neurooncology, Vol. 107, No. 1, 2012, pp. 155-164. doi:10.1007/s11060-011-0722-2

has been cited by the following article:

• TITLE: The Complexities of Resistance to Bevacizumab

  AUTHORS: Han Shen, Kerrie L. McDonald

  KEYWORDS: Glioblastoma; Bevacizumab; Relapse; Glycolysis

  JOURNAL NAME: Journal of Cancer Therapy, Vol.3 No.5, October 17, 2012

  ABSTRACT: Glioblastoma is a highly malignant primary tumor of the central nervous system tumor with a poor survival rate. The treatment of glioblastoma is shifting from a purely cytotoxic approach to one that incorporates anti-angiogenic agents. Bevacizumab (Avastin; Roche) was approved in the United States for the treatment of recurrent glioblastoma in May 2009 and showed encouraging results. However, “rebound” tumor progression with accelerated clinical decline has been observed after cessation of bevacizumab therapy in patients with high-grade gliomas and there is no effective treatment for the recurrent glioblastoma after bevacizumab failure. This review summarizes the characteristics of glioblastoma as well as the possible mechanisms of recurrence after anti-angiogenic therapy. Furthermore, alterations of the key molecular pathways and glycometabolic remodeling in glioblastoma are also discussed within. A better understanding of the complexities underpinning the resistance to bevacizumab and the combination of targeting cancer metabolism and anti-VEGF therapy may ultimately result in new modes of treatment, which hopefully improve the overall survival for patients diagnosed with glioblastoma.